ArticleJournal of medical biochemistry2026
The clinical evaluation value of the NRF2-mediated antioxidant stress mechanism in elderly patients with type 2 diabetes mellitus complicated by osteoporosis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of nuclear factor erythroid 2-related factor 2 (NRF2) as a central transcription factor in the regulation of cellular antioxidant stress is of significant interest, particularly in its potential clinical relevance for elderly patients with type 2 diabetes mellitus (T2DM)-associated osteoporosis (T2DM-OP). Methods: A cohort of 196 patients with T2DM who received treatment were recruited and stratified into three groups according to T-scores derived from bone mineral density (BMD) assessments. Serum concentrations of 25-hydroxyvitamin D3, osteocalcin (OC), procollagen type I N-terminal propeptide (P1NP), b-isomerized C-terminal telopeptide of type I collagen (b-CTX), as well as nuclear factor erythroid 2-related factor 2 (NRF2), superoxide dismutase (SOD), and malondialdehyde (MDA) were quantified utilizing enzyme-linked immunosorbent assay techniques. Pearson correlation analysis was conducted to explore the relationships among NRF2, SOD, MDA, and BMD. Additionally, multivariate logistic regression analysis was employed to investigate the association between Asprosin levels and the risk of T2DM-OP. Results: There were no apparent differences in baseline characteristics (gender, age, BMI, duration of diabetes mellitus, and metabolic parameters) among the three groups (P > 0.05). Analysis revealed that lumbar spine BMD decreased evidently with declining bone mass (normal bone mass group 1.13 g/cm2, osteopenia group 0.93 g/cm2, osteoporosis group 0.80 g/cm2, P < 0.001). In the osteoporosis cohort, there was a significant elevation in the bone resorption marker b-CTX and the bone formation marker OC (P < 0.001), indicating a pronounced imbalance in bone turnover. Among oxidative stress factors, SOD activity and NRF2 levels progressively decreased with bone loss, while MDA levels increased (all P < 0.001), indicating declined antioxidant capacity and aggravated oxidative damage. Correlation analysis showed that NRF2 and SOD were positively correlated with BMD, whereas MDA was negatively correlated with BMD. Multivariate logistic regression further confirmed that low NRF2, low SOD, and high MDA were independent risk factors for T2DM-OP (P < 0.05). Receiver operating characteristic curve analysis demonstrated that NRF2 exhibited high sensitivity (80.36%) and specificity (77.86%) in predicting T2DM-OP with an area under the curve of 0.856 (95% CI: 0.803-0.909, P < 0.001), comparable to bone turnover indicators. Conclusions: The study reveals that the NRF2-mediated antioxidant response is crucial in the pathological progression of T2DM-OP highlighting its potential as a new therapeutic target for prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.